U.S. FDA Approves Generic Version Of Exparel, (Bupivacaine Liposome) A Non-Opioid Used For Post-surgery Local Anasthesia, Approval Of An Abbreviated NDA For A Generic Version From Hengrui Pharma
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved a generic version of Exparel (Bupivacaine Liposome), a non-opioid used for post-surgery local anesthesia. The approval was granted to Hengrui Pharma.
July 02, 2024 | 7:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The FDA's approval of a generic version of Exparel (Bupivacaine Liposome) by Hengrui Pharma could negatively impact Pacira BioSciences (PCRX), the original manufacturer of Exparel.
Pacira BioSciences (PCRX) is the original manufacturer of Exparel. The approval of a generic version by Hengrui Pharma introduces competition, which could lead to a decrease in market share and revenue for PCRX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100